What if just like blood pressure, we could measure the complexity of the brain?
HealthTech Connex, a neuro-health technology company has made it possible through its industry-leading medical device, the NeuroCatch® Platform, that could record your brain’s objective, and physiological responses quickly across various brain conditions, including brain injuries, neurological diseases, mental health and brain optimization.
The company runs on the following business model to make optimal brain health possible:
- Measure: Offering an objective evaluation of cognitive functions, which is delivered in minutes at the point of care.
- Test: Administering high-quality research services to advance healthcare innovations for a positive impact on brain health.
- Treat: Focusing on comprehensive therapies using advanced, non-invasive brain technologies to help treat people with neurological conditions.
In an interview with Insights Care, Dr. Ryan C. N. D’Arcy, the President and Chief Scientific Officer, talks about the company’s contribution to enabling care for neurological conditions like concussion and brain injury, dementia, PTSD, mental health and more.
Following are the excerpts from the interview.
Kindly tell us the source of inspiration. What led you to venture into the Neurotech industry?
We are neuroscience and neuroimaging experts who develop and run some of the most advanced hospital-embedded brain imaging labs in the world. The foundational problem was that – as powerful as these amazing labs are – they continue to be completely inaccessible to the frontline points of care. The NeuroCatch® Platform was developed as the solution to this major barrier in state-of-the-art brain health: to bring the most sensitive and objective evaluation to all points needed on this planet and beyond.
Brief us about yourself and shed some light on your role and responsibility at the company.
I’m a Canadian neuroscientist, researcher, innovator and entrepreneur. Being an endowed university professor, I’m a world-renowned expert in neurotechnology. I’ve co-founded HealthTech Connex Inc. (HTC) and serve as President and Chief Scientific Officer. HealthTech Connex translates neuroscience advances into health technology breakthroughs.
What are the mission, vision and values shared by the company?
The mission of HealthTech Connex (HTC) is to positively impact a billion brains. In medicine, you can’t treat what you can’t measure. Accordingly, our vision is to launch the NeuroCatch® Platform globally as the most accessible, sensitive and highest-quality evaluation of cognitive brain health and performance. NeuroCatch® technology is deployed in clinical trials and identifying novel, effective treatment interventions. These evidence-based innovative treatments are scaling up to positively impact people through our clinic and network of clinics.
Tell us about the core products and services that the company offers to support the needs of the clients/patients. How are these different from other companies in the market?
HTC’s family of businesses works together to attract the latest and greatest healthcare innovations for brain and mental health. With clinical neuroscience and brain vitality as a premier focus, we connect science and R&D to product breakthroughs—providing translational neuroscience innovations to care sectors and communities worldwide.
HealthTech Connex exists as the parent company for 3 entities, driving an HTC flywheel model:
NeuroCatch Inc. – The NeuroCatch® Platform (NCP)
The NeuroCatch® Platform (NCP) is an industry-leading medical device that offers an objective evaluation of cognitive function, which is delivered in minutes at the point of care. NeuroCatch® is deployed in hospitals, clinics, sports venues, care homes, high schools, and space missions.
Centre for Neurology Studies (CNS)
The Centre for Neurology Studies (CNS) runs clinical trials in the field of neuroscience and brain health, the core focus revolving around medical devices and pharma in neurological populations. The CNS team works with global partners to build evidence-based treatments from start-up studies to international, multi-site clinical trials.
Surrey Neuroplasticity Clinic (SNPC)
The Surrey Neuroplasticity Clinic (SNPC) deploys all emerging innovations identified by NeuroCatch® and validated by CNS clinical trials through our clinic and growing network of clinics in North America.
Brief us about the rising need for neurotechnology in the healthcare sector. How will it impact the way patients receive treatment and the clinical decisions taken by care providers?
The critical need for an accessible and objective measure of brain health is essential for managing and preventing tragic brain health injuries and diseases. As a leading R&D company, we have developed NeuroCatch® as a solution to this problem.
What specific R&D operations is your company leading at present? Why do you find them essential in developing or improving neurotech solutions?
HTC is a science-based company, with established leadership and breakthrough technology. Specific R&D focus continues to make NeuroCatch® even more accessible and powerful through software and hardware advances to empower clinical-grade treatments and unleash optimized brain performance.
What advice would you like to give to budding entrepreneurs and enthusiasts who desire to venture into the neurotech Industry?
Now is the time. Neurotech is one of the most exciting emerging industries, with unimaginable potential to address the wickedest problems humanity faces.
How do you envision scaling the company’s services and operations in 2023 and beyond?
The current generation of NeuroCatch® is scaling in North America and preparing for global expansion. In parallel, the next generation of NeuroCatch® is beginning development to be faster, easier and more accessible with expanded brain health evaluation capabilities. Design-inspired by ubiquitous vital signs, soon NeuroCatch® will be as accessible as blood pressure to enable regular brain health management and optimization. The technology will scale further to find innovative treatments that challenge our most devastating brain injuries and diseases. We anticipate the emergence of this scaling within 5 years.
